Nitric oxide delivery in stagnant systems via nitric oxide donors: a mathematical model
- PMID: 12693025
- DOI: 10.1021/tx025528r
Nitric oxide delivery in stagnant systems via nitric oxide donors: a mathematical model
Abstract
As a small biological molecule, nitric oxide (NO), plays a key role in diverse functions including smooth muscle cell regulation, neurotransmission, inhibition of platelet aggregation, and cytotoxic actions. The assessment of NO effects in biological systems has extensively been studied using NO donor compounds that often have differing NO release mechanisms and kinetic rates. Due to the differing kinetic rates and release mechanisms, in addition to reactions involving NO (such as autoxidation of NO), the NO concentrations to which biological systems are exposed may vary significantly depending upon the NO donor compound. Thus, quantifying the effects of NO using different NO donors is difficult unless the NO concentration profile in the experimental system is predicted or measured. In this study, the spatial and temporal NO concentration in a stagnant system (such as a culture plate or micro-well) is modeled following the addition of an NO donor characterized with first-order NO release kinetics. Two NO donors were utilized: diethylamine NONOate (DEA/NO) and spermine NONOate (SPER/NO). The use of a mathematical model can eliminate the need of complex in situ NO measurements and be useful for predicting the physical loss of NO from the experimental system. In addition, properly scaling the NO concentration can be useful in estimating the maximum NO concentration that will exist in solution. The results show that under widely used in vitro experimental conditions, including varying NO donor concentrations, cellular oxygen consumption rates, and aqueous phase heights, the spatial and temporal NO concentration range can vary significantly. In addition, hypoxic conditions can occur in the vicinity of cells, and in some situations, the physical loss of NO from the experimental system may be significant.
Similar articles
-
Measurement and modeling of nitric oxide release rates for nitric oxide donors.Chem Res Toxicol. 1997 Apr;10(4):408-13. doi: 10.1021/tx960183w. Chem Res Toxicol. 1997. PMID: 9114977
-
Complexes of nitric oxide with nucleophiles as agents for the controlled biological release of nitric oxide: antiplatelet effect.Thromb Haemost. 1993 Oct 18;70(4):654-8. Thromb Haemost. 1993. PMID: 8115991
-
Nitric oxide donors: novel cancer therapeutics (review).Int J Oncol. 2008 Nov;33(5):909-27. Int J Oncol. 2008. PMID: 18949354 Review.
-
Novel devices for the predictable delivery of nitric oxide to aqueous solutions.Chem Res Toxicol. 1998 Nov;11(11):1346-51. doi: 10.1021/tx980112s. Chem Res Toxicol. 1998. PMID: 9815196
-
Nitric oxide-donating materials and their potential in pharmacological applications for site-specific nitric oxide delivery.Future Med Chem. 2009 Nov;1(8):1497-507. doi: 10.4155/fmc.09.111. Future Med Chem. 2009. PMID: 21426062 Review.
Cited by
-
Recent developments in nitric oxide donor drugs.Br J Pharmacol. 2007 Jun;151(3):305-21. doi: 10.1038/sj.bjp.0707224. Epub 2007 Apr 2. Br J Pharmacol. 2007. PMID: 17401442 Free PMC article. Review.
-
Inhibition of anti-IgE mediated human mast cell activation by NO donors is dependent on their NO release kinetics.Br J Pharmacol. 2009 Apr;156(8):1279-86. doi: 10.1111/j.1476-5381.2009.00120.x. Epub 2009 Mar 19. Br J Pharmacol. 2009. PMID: 19302592 Free PMC article.
-
Extracellular diffusion and permeability effects on NO-RBCs interactions using an experimental and theoretical model.Microvasc Res. 2010 Jan;79(1):47-55. doi: 10.1016/j.mvr.2009.10.002. Epub 2009 Oct 23. Microvasc Res. 2010. PMID: 19837099 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials